Arcturus Therapeutics (ARCT) shares soared 8.7% in the last trading session to close at $19.62. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4% gain over the past four weeks.The sudden uptick can be attributed to positive investor mindset regarding the potential of ARCT’s wholly-owned pipeline comprising two mRNA therapeutic candidates, ARCT-810 and ARCT-032, undergoing mid-stage development for ornithine transcarbamylase defi ...